Sign in

CIK 0001907108

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Lexeo Therapeutics, Inc.

Sign in to watch
Ticker
LXEO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
854012572
Phone
+1 212-547-9879
Business address
345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK, NY, 10010
  1. 4 Open-market sale Chief Technical Officer sold 2,115 shares at an average $8.94 ($18,913)
  2. 4 Open-market sale Chief Medical Officer sold 3,382 shares at an average $8.94 ($30,242)
  3. 4 Open-market sale Chief Executive Officer sold 13,133 shares at an average $8.94 ($117,436)
  4. 4 Grant or award Chief Executive Officer acquired 2,193 shares (grant or award)
  5. 4/A Open-market sale Chief Executive Officer sold 1,115 shares at $4.67 ($5,205)
  6. 4 Grant or award Chief Financial Officer acquired 45,000 shares (grant or award)
  7. 3 Insider Initial Statement of Ownership
  8. 4 Open-market sale Chief Technical Officer sold 2,848 shares at $4.67 ($13,294)
  9. 4 Open-market sale Chief Legal Officer sold 542 shares at $4.67 ($2,530)
  10. 4 Open-market sale Chief Medical Officer sold 608 shares at $4.67 ($2,838)
  11. 4 Open-market sale Chief Executive Officer sold 2,735 shares at $4.67 ($12,767)
  12. 4 Open-market sale Chief Development Officer sold 382 shares at $4.67 ($1,783)
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Open-market sale Chief Executive Officer sold 1,074 shares at $2.77 ($2,979)

Page 3 of 7 · 121 filings